Barinthus Biotherapeutics plc (BRNS) Stock Analysis
DELISTED
What happened to Barinthus Biotherapeutics plc (BRNS) stock?
Barinthus Biotherapeutics plc (BRNS) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $30.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Barinthus Biotherapeutics plc (BRNS). Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on innovative T-cell immunotherapies targeting chronic infectious diseases, autoimmune disorders, and various cancers.
Last analyzed: Jun 14, 2026These figures come from statements filed 13 months ago — the most recent this company has published.
Barinthus Biotherapeutics plc (BRNS) Healthcare & Pipeline Overview
Barinthus Biotherapeutics plc ADR Information Sponsored
Barinthus Biotherapeutics plc (BRNS) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy BRNS shares?
No. BRNS stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for BRNS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BRNS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Barinthus Biotherapeutics plc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.